Dimerix Limited (ASX:DXB) Filings

Dimerix Limited

Filings

FilingDateTypeFiled with
Final Director's Interest Notice - MDNov 5, 2026Ownership change noticeASX
Dimerix Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Dimerix Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
New Data Supports Biological Rationale for DMX-200 in FSGSOct 22, 2026Other filingsASX
2026 AGM Notice of Meeting, Letter of Access and Proxy FormOct 21, 2026Meeting noticeASX
Dimerix Announces Board Chair TransitionOct 18, 2026Management or board changeASX
DMX-200 First 100 Patients Complete Phase 3 Trial TreatmentOct 15, 2026Operations updateASX
Dimerix at Canaccord Drug & Device and Ignite ConferencesOct 11, 2026Operations updateASX
First Patient Reaches Four Years in DMX-200 Clinical ProgramOct 4, 2026Other filingsASX
Notification regarding unquoted securities - DXBSep 28, 2026Other filingsASX
Notification of 2026 Annual General Meeting DateSep 25, 2026Meeting noticeASX
Dimerix Draws Down A$17M Under Non-Dilutive Funding FacilitySep 22, 2026FinancingASX
Dimerix Presents at ASX SMIDcaps Conference 2026Sep 22, 2026Other filingsASX
Waiver of Listing Rule 10.1 GrantedSep 22, 2026Other filingsASX
Dimerix Presents at E&P Healthcare Conference 2026Sep 15, 2026Other filingsASX
Dimerix DMX-652 Granted Mexican Composition of Matter PatentSep 13, 2026Other filingsASX
Dimerix Investor PresentationSep 6, 2026Other filingsASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
Dimerix Secures A$34 Million Non-Dilutive Funding FacilitySep 3, 2026FinancingASX
Trading HaltSep 1, 2026Trading halt or suspensionASX
Appendix 4E and 2026 Annual ReportAug 26, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 26, 2026Other filingsASX
Dimerix Receives US$10M Upfront Payment from EverestAug 19, 2026Other filingsASX
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652Aug 16, 2026Other filingsASX
Dimerix Presents at Bioshares Summit 2026Aug 5, 2026Other filingsASX
Dimerix Quarterly Activities Report and Appendix 4CJul 29, 2026Quarterly reportASX
US Patent Granted for Dimerix New Asset DMX-652Jul 22, 2026Other filingsASX
Dimerix Expands Pipeline with Acquisition of Phase 2 AssetJul 16, 2026Acquisition or disposalASX
Dimerix Non-Dilutive Funding Builds Pipeline, Boosts RunwayJul 16, 2026FinancingASX
DMX-200 Available To Patients Via Post-Trial Access PathwaysJul 8, 2026Operations updateASX
Dimerix Licenses DMX200 to Everest for China and Asia RegionJun 15, 2026Other filingsASX
Dimerix Quarterly Activities Report and Appendix 4CApr 29, 2026Quarterly reportASX
ACTION3 Statistical Review CompleteApr 27, 2026Other filingsASX
Dimerix to Conduct Review of ACTION3 Statistical AssumptionsMar 15, 2026Other filingsASX
Dimerix Phase 3 Trial Last Patient Receives First DoseMar 9, 2026Operations updateASX
Appendix 4D and Half Year Financial ReportFeb 25, 2026Interim reportASX
Quarterly Appendix 4C and Activities ReportJan 28, 2026Quarterly reportASX
BioMarin to acquire Dimerix US Partner, Amicus TherapeuticsDec 21, 2025Acquisition or disposalASX
DMX-200 ACTION3 Phase 3 Trial Completes RecruitmentDec 14, 2025Operations updateASX
Successful Completion of Planned IDMC ReviewNov 18, 2025Other filingsASX
Successful PARASOL Collaboration Data Analysis OutcomeOct 7, 2025Other filingsASX
DMX-200 receives Orphan Drug Designation in JapanSep 29, 2025Other filingsASX
Appendix 4E and 2025 Annual ReportAug 27, 2025Annual reportASX
Dimerix receives 1st Development Milestone payment from FUSOJun 29, 2025Other filingsASX
ACTION3 Clinical Trial Milestone Recruitment UpdateJun 12, 2025Other filingsASX
1st ACTION3 site in Japan activated and milestone triggeredMay 29, 2025Other filingsASX
Successful planned IDMC review of ACTION3 trialMay 21, 2025Other filingsASX
Dimerix receives initial upfront payment from AmicusMay 5, 2025Other filingsASX
Investor Webinar and PresentationApr 30, 2025Other filingsASX
Dimerix Licenses DMX-200 in the USApr 30, 2025Other filingsASX
Trading HaltApr 28, 2025Trading halt or suspensionASX
FDA confirms Proteinuria as Primary Endpoint for US approvalApr 27, 2025Operations updateASX
S&P DJI Announces March 2025 Quarterly RebalanceMar 7, 2025Other filingsASX
Dimerix receives initial upfront payment from FUSOMar 3, 2025Acquisition or disposalASX
Half-Year Financial Report & Appendix 4D - 31 December 2024Feb 24, 2025Interim reportASX
First Paediatric Patient Recruited for ACTION3Jan 15, 2025Other filingsASX
Dimerix enters Development and License Agreement for JapanJan 6, 2025Other filingsASX
DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment CompleteDec 29, 2024Other filingsASX
Dimerix Receives $7.9M R&D Tax Incentive RebateNov 14, 2024Other filingsASX
NEPTUNE Study Network to Enhance Phase 3 Recruitment in USOct 31, 2024Other filingsASX
Project PARASOL Update & Medical Advisory Board AppointmentOct 27, 2024Operations updateASX
ACTION3 Trial Recruitment and Multiregion Trial Site UpdateSep 15, 2024Operations updateASX
First Paediatric Site Activated and Trial UpdateSep 11, 2024Other filingsASX
First patient enters into Open Label Extension studySep 10, 2024Other filingsASX
Preliminary Final ReportAug 28, 2024ResultsASX
Adolescent Recruitment into ACTION3 Clinical TrialJul 3, 2024Other filingsASX
Dimerix and Taiba enter into License Agreement for DMX-200May 26, 2024Other filingsASX
Dimerix Receives PIP Approval from the UK MHRAApr 30, 2024Other filingsASX
Dimerix Completes $20M PlacementMar 11, 2024FinancingASX
Dimerix Successfully Passes Efficacy Interim AnalysisMar 10, 2024Operations updateASX
PH3 Data Collection Complete for First Interim AnalysisFeb 26, 2024Other filingsASX
Half-Year Financial Report & Appendix 4D - 31 December 2023Feb 25, 2024Interim reportASX
ACTION3 IND Approved in ChinaNov 27, 2023Operations updateASX
Dimerix Receives Initial Upfront Payment from Advanz PharmaNov 5, 2023Other filingsASX
Dimerix Announces License Agreement for EU, Canada, ANZOct 4, 2023Other filingsASX
FDA Approves Qytovra Brand NameSep 24, 2023Operations updateASX
Regulatory Approval received in Malaysia for ACTION3 StudySep 21, 2023Operations updateASX
Dimerix Receives $8.9M R&D Tax Incentive RebateSep 12, 2023Other filingsASX
Successful Completion of 2nd DSMB Review of FSGS TrialAug 7, 2023Other filingsASX
DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24Jul 23, 2023Other filingsASX
Approval received for Paediatric Investigation Plan from EMAJul 4, 2023Legal or regulatory actionASX
Dimerix confirms Phase 3 study design appropriate for ChinaJul 2, 2023Other filingsASX
ProspectusJun 26, 2023Offer documentASX
Dimerix Announces Update on Successful Capital RaiseJun 5, 2023Other filingsASX
Rights Issue ProspectusMay 4, 2023FinancingASX
Reinstatement to Official QuotationMay 3, 2023Trading halt or suspensionASX
Entitlement offer and Convertible Note to raise $12 millionMay 3, 2023FinancingASX
Voluntary SuspensionMay 2, 2023Trading halt or suspensionASX
Half-Year Financial Report & Appendix 4D - 31 December 2022Feb 26, 2023Interim reportASX
DXB to Receive $2.8m in Prepayment of R&D Tax IncentiveFeb 16, 2023Other filingsASX
Successful Completion of DSMB Review of Phase 3 FSGS TrialFeb 8, 2023Other filingsASX
FDA Confirms Inclusion of Paediatrics in ACTION3 StudyJan 11, 2023Other filingsASX
DMX-200 FSGS Phase 3 Trial Part 1 Recruitment AchievedDec 14, 2022Other filingsASX
CLARITY 2.0 COVID-19 Study OutcomeDec 12, 2022Other filingsASX
Chair address and CEO presentation to AGMNov 28, 2022Other filingsASX
Dimerix Receives A$6.0M R&D Tax Incentive RebateOct 24, 2022Other filingsASX
Appendix 4E and 2022 Annual ReportAug 28, 2022Annual reportASX
CLARITY 2.0 COVID-19 Study Concludes RecruitmentAug 17, 2022Other filingsASX
New Patent Family Application for DMX-700Aug 8, 2022Other filingsASX
DMX-700 Study Shows Significant 80% Reduction in Lung InjuryJul 3, 2022Other filingsASX
REMAP-CAP COVID-19 Study Analysis UpdateJun 26, 2022Other filingsASX
New Clinical Trial for DMX-200 in Diabetic Kidney DiseaseJun 6, 2022Other filingsASX
Phase 3 FSGS Kidney Trial First Patient RecruitedMay 30, 2022Other filingsASX
Dimerix presentation at Bioshares Biotech SummitMay 11, 2022Other filingsASX
FDA IND Approval for Phase 3 Study of DMX-200 in FSGSMay 8, 2022Other filingsASX
Dimerix Receives A$3.7M R&D Tax Incentive RebateMar 28, 2022Other filingsASX
DSMB Change to REMAP-CAP COVID-19 StudyFeb 27, 2022Other filingsASX
Half-Year Financial Report & Appendix 4D - 31 December 2021Feb 23, 2022Interim reportASX
First Regulatory Approval in Europe for DMX-200 FSGS StudyFeb 1, 2022Other filingsASX
Patients Dosed in DMX-200 COVID-19 Phase 3 Study in IndiaJan 10, 2022Other filingsASX
Ethics Approval in Australia for Phase 3 COVID-19 StudyDec 22, 2021Other filingsASX
DSMB Recommends Continuation of Ph3 COVID-19 Study in EuropeDec 16, 2021Other filingsASX
Pause in TradingDec 15, 2021Trading halt or suspensionASX
First Approvals Received for Start of Phase 3 FSGS TrialOct 20, 2021Other filingsASX
Phase 3 DMX-200 COVID-19 Study Expands into AustraliaOct 14, 2021Other filingsASX
Dimerix Closes SPP OversubscribedSep 30, 2021Other filingsASX
DMX-200 CLARITY COVID-19 Study Approval in IndiaSep 24, 2021Other filingsASX
Phase 3 Study in FSGS Kidney Patients CommencesAug 24, 2021Other filingsASX
SPP and Options ProspectusAug 23, 2021Offer documentASX
Response to ASX QueryAug 19, 2021Explanation requestASX
Successful $20m Placement to Fund Phase 3 TrialsAug 15, 2021FinancingASX
DMX-200 COVID-19 Study Opens More Sites in Europe and UKAug 1, 2021Other filingsASX
FDA Confirms Phase 3 Study Design in FSGS Kidney DiseaseJul 18, 2021Other filingsASX
Dimerix Receives Innovation Passport and ILAP DesignationJun 6, 2021Other filingsASX
Dimerix Confirms Phase 3 FSGS Study Design With EMAJun 3, 2021Other filingsASX
DMX-200 Remains Eligible for Accelerated ApprovalMay 27, 2021Other filingsASX
COVID-19 Study Recruits Multiple Patients in EuropeApr 22, 2021Other filingsASX
Major Shareholder Loan for $5 MillionMar 29, 2021Other filingsASX
Clinical Study in Patients with COVID-19 ProgressesMar 24, 2021Other filingsASX
DMX-200 Competitive Position Further EnhancedMar 23, 2021Other filingsASX
CLARITY 2.0 Study Progresses In Patients With COVID-19Mar 9, 2021Other filingsASX
Appendix 4D and Interim Financial ReportFeb 21, 2021Interim reportASX
Dimerix Plans for Next Study in Diabetic Kidney DiseaseJan 27, 2021Other filingsASX
Second Study to Include DMX-200 in COVID-19 PatientsNov 29, 2020Other filingsASX
ARDS in COVID-19 Patients Protocol PublishedNov 8, 2020Other filingsASX
Positive Additional Data to Support DMX-200 DevelopmentOct 26, 2020Other filingsASX
Receipt of R&D Tax IncentiveOct 20, 2020Other filingsASX
DMX-700 Data Demonstrates Effect on Key COPD ReceptorsOct 6, 2020Other filingsASX
Positive Top-Line Results in DKD Phase 2 Clinical StudySep 13, 2020Other filingsASX
Dimerix Awarded $1 Million MRFF FundingSep 2, 2020Other filingsASX
Positive Top-Line Results in FSGS Phase 2a Clinical StudyJul 28, 2020Other filingsASX
Last Patient Completes Dosing in DKD Phase 2 Clinical StudyJul 23, 2020Other filingsASX
Dimerix Completes $5.8m PlacementJun 22, 2020FinancingASX
Last Patient Completes Dosing in FSGS Phase 2 Clinical StudyJun 16, 2020Other filingsASX
Global REMAP-CAP Platform Trial Protocol To Include DMX-200Jun 3, 2020Other filingsASX
R&D Tax Incentive FacilityApr 2, 2020Other filingsASX
DMX-200 Treatment Continued Under TGA Special Access SchemeMar 2, 2020Other filingsASX
Half Yearly Report and AccountsFeb 18, 2020Interim reportASX
Quarterly Commentary & Appendix 4CJan 20, 2020Quarterly reportASX
DMX-200 Clinical Trial UpdateJan 6, 2020Other filingsASX
Dimerix Completes $2.5m PlacementDec 2, 2019FinancingASX
Dimerix Holds Pre-IND Meeting on DMX-200 With FDANov 24, 2019Other filingsASX
New Drug Pipeline Candidate DMX-700 & Company UpdateOct 9, 2019Other filingsASX
DMX-200 Phase 2 Clinical Study in DKD Completes RecruitmentSep 25, 2019Other filingsASX
DMX-200 Phase 2 Clinical Trial in FSGS Fully RecruitedJul 9, 2019Other filingsASX
DMX-200 Clinical UpdateJun 25, 2019Other filingsASX
Dimerix Signs Licence Agreement for Receptor-HIT TechnologyJun 23, 2019Other filingsASX
DMX-200 Manufacturing UpdateMay 26, 2019Other filingsASX
Appendix 4C - quarterlyApr 26, 2019Quarterly reportASX
Appendix 4C and Quarterly HighlightsJan 30, 2019Quarterly reportASX
Dimerix Receives R&D Tax Cash Rebate Totalling $1.07mDec 19, 2018Other filingsASX
1st Patient Dosed in DMX-200 Clinical Trial for FSGSNov 21, 2018Other filingsASX
DXB Receives Orphan Drug Designation in EUNov 20, 2018Other filingsASX
FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIALNov 19, 2018Other filingsASX
EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENTAug 26, 2018Other filingsASX
Quarterly Review & Appendix 4CJul 31, 2018Quarterly reportASX
Ethics Approval Received Appendix 3B and S.708A NoticeJul 18, 2018FinancingASX
Further US patent allowed for DMX-200Jul 1, 2018Other filingsASX
Dual Phase 2 trials launched for CKDMay 14, 2018Other filingsASX
Westar Capital Retained as Corporate AdvisorsApr 12, 2018Other filingsASX
CMO Appointment and Clinical Trials UpdateMar 26, 2018Other filingsASX
Half Year Report and Financial StatementsFeb 26, 2018Interim reportASX
Oversubscribed Placement to Raise a Further $4.5mFeb 20, 2018FinancingASX
Quarterly Review and Appendix 4CJan 29, 2018Quarterly reportASX
Results of Entitlement OfferJan 23, 2018FinancingASX
DMX-200 Dosage Optimisation Study Successfully CompletedJan 7, 2018Other filingsASX
Proteomics partnership to improve treatment of CKDDec 13, 2017Other filingsASX
Entitlement Offer BookletDec 5, 2017FinancingASX
Entitlement Offer to raise $5.5 millionDec 5, 2017FinancingASX
Suspension from Official QuotationDec 4, 2017Trading halt or suspensionASX
Dimerix Phase 2a Subgroup Analysis ResultsNov 1, 2017Other filingsASX
Ethics Committee Approval for Pharmacokinetic TrialOct 23, 2017Other filingsASX
Dimerix Receives $545k R&D Tax RefundOct 17, 2017Other filingsASX
Notice of Annual General Meeting/Proxy FormSep 12, 2017Meeting noticeASX
DMX-200 tablet manufacture and human study timelineSep 4, 2017Other filingsASX
Positive Results from Phase 2a Trial of DMX-200Jul 12, 2017Other filingsASX
Research Validates Relevance of DMX Receptor-HIT TechnologyJun 12, 2017Other filingsASX
Investor UpdateApr 10, 2017Other filingsASX
Receipt of $420k Research & Development Tax RefundMar 21, 2017Other filingsASX
Corporate PresentationFeb 13, 2017Other filingsASX
Key Patent Allowed in JapanJan 30, 2017Other filingsASX
Dimerix Raises $2 million to Advance Clinical ProgramJan 24, 2017Other filingsASX
Recruitment of Part A of Phase 2 Trial of DMX-200 CompletedDec 5, 2016Other filingsASX
Appointment of Chief Executive OfficerNov 6, 2016Management or board changeASX
Update presentation - interim dataOct 11, 2016Other filingsASX
Positive interim analysis of DMX-200 phase II dataOct 3, 2016Other filingsASX
Appendix 4EAug 24, 2016ResultsASX
Response to ASX Price and Volume QueryAug 15, 2016Explanation requestASX
Outcomes of DMX-200 pre-IND meeting with the FDAAug 1, 2016Other filingsASX
Update for NASH Pre-Clinical ProgramJul 28, 2016Other filingsASX

This page holds 200 of 242 filings.